Phosphromycin is expected to treat the deadly lester bacteria

In a recent study published in the international journal PLoS Genetics, scientists from the University of Edinburgh found that bacteria thought to be resistant to powerful antibiotics may eventually become sensitive to treatment;in the
study, researchers found that an antibiotic called phosphromycin may be used as a new treatment for fatal Lester infections, and early laboratory tests have shown that phosphatoxine does not appear to kill Lester because the bacteria carry special genes that break down phosphromycin; However, as researchers further found in laboratories and mice, phosphromycin may be effective in killing the bacteria in infected cells, and only when the bacteria infect the body will the genes they carry be activated, effectively counteracting the effects of the drug on the killing of bacteria.
-related results show that although laboratory tests suggest that bacteria can develop some resistance to antibiotics, phosphromycin can still be used as an effective treatment for fatal Lester infection, a lester infection commonly known as Lester's disease, which is one of the most deadly food-eating diseases, usually caused by the intake of food contaminated with Lester bacteria, such as meat, salads and cheese. For people with weakened immune systems, such as the elderly and newborns, the infection is fatal, and the Lester infection can induce miscarriages in pregnant women.
These bacteria also multiply in the body's cells and frequently affect brain health, currently only special drugs can be treated, which undoubtedly limits clinicians' treatment of severe Lester bacteria, so this study points out that phosphromycin can effectively treat patients infected with Lester bacteria Finally, researcher Professor Jose Vazquez-Boland points out that in this study, we focused on listeria, and that the results may also be used in the treatment of other bacterial infections, and we will continue to look for other drugs to overcome current bacterial resistance at a later stage. (Bio Valley)